naltrexone Archives - Well Referenced

Combination Therapy with Naltrexone and Bupropion for Obesity Reduces Total and Visceral Adiposity

This 2013 study assessed the impact of combined naltrexone/bupropion therapy on body composition in 107 obese adults over 24 weeks. Participants were randomized to receive placebo, naltrexone monotherapy, bupropion monotherapy, or one of three naltrexone/bupropion combinations. Body composition was measured using dual-energy X-ray absorptiometry and computed tomography. The combination therapy

June 26, 2025 No Comments

Naltrexone Sustained-Release/Bupropion Sustained-Release for the Management of Obesity: Review of the Data to Date

This 2014 systematic review evaluates the efficacy and safety of the naltrexone sustained-release/bupropion sustained-release (NB SR) combination, marketed as Contrave®, for obesity management. Clinical trials indicate a placebo-subtracted weight loss of approximately 4.5%, comparable to other anti-obesity medications. The combination targets central nervous system pathways to reduce appetite and food

June 26, 2025 No Comments

A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept

This 2014 pilot study evaluated the efficacy of naltrexone (25 mg/day) in mitigating antipsychotic-induced weight gain in 24 overweight women diagnosed with schizophrenia or schizoaffective disorder. Over an 8-week period, participants receiving naltrexone experienced a significant mean weight loss of 3.40 kg, whereas those on placebo gained an average of

June 26, 2025 No Comments

The Opioid Antagonist Naltrexone Improves Murine Inflammatory Bowel Disease

This 2008 preclinical study investigated the effects of naltrexone, an opioid receptor antagonist, on inflammatory bowel disease (IBD) in murine models. The findings demonstrated that naltrexone administration led to significant improvements in colitis symptoms, including reduced inflammation and mucosal damage. The proposed mechanism involves modulation of the immune response through

June 26, 2025 No Comments

Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis

This systematic review and meta-analysis evaluated the safety profile of oral naltrexone by analyzing serious adverse events (SAEs) reported in placebo-controlled randomized controlled trials (RCTs). A total of 89 RCTs involving 11,194 participants across various conditions—including alcohol use disorders, psychiatric disorders, impulse control disorders, obesity, Crohn’s disease, fibromyalgia, and cancer—were

June 26, 2025 No Comments

Successive Treatment with Naltrexone Induces Epithelial-Mesenchymal Transition and Facilitates the Malignant Biological Behaviors of Bladder Cancer Cells

This 2021 in vitro study examined the impact of chronic naltrexone exposure on bladder cancer cell lines (T24 and MB49). It demonstrated that successive treatment enhanced proliferation, migration, and invasion while inhibiting apoptosis. Mechanistically, naltrexone induced epithelial-mesenchymal transition (EMT) by downregulating epithelial markers (E-cadherin, CK19) and upregulating mesenchymal markers (N-cadherin,

June 26, 2025 No Comments

Naltrexone’s Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures

This 2021 systematic review evaluates the effects of naltrexone (NTX), including low-dose naltrexone (LDN), on cancer progression and mortality across human, animal, and cell culture studies. Findings indicate that LDN (3–5 mg/day) may inhibit tumor growth and metastasis, potentially by modulating opioid receptors and immune responses. Conversely, high-dose or continuous

June 26, 2025 No Comments

Treatment of Idiopathic Erectile Dysfunction in Men with the Opiate Antagonist Naltrexone—A Double-Blind Study

This double-blind, placebo-controlled study assessed the efficacy of naltrexone, an opioid receptor antagonist, in treating idiopathic erectile dysfunction (ED) in 20 otherwise healthy men aged 23.9–63.3 years. Participants received 25 mg/day of naltrexone or placebo for 4 weeks, followed by 50 mg/day or placebo for another 4 weeks. Daily logs

June 26, 2025 No Comments

Tag: naltrexone